Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells

Molecular Cell

Volumn 3, Issue 3, 1999, Pages 389-395

  Xu, Xiaoling ^a   Weaver, Zoë ^b,c   Linke, Steven P ^c   Li, Cuiling ^a   Gotay, Jessica ^a   Wang, Xin Wei ^c   Harris, Curtis C ^c   Ried, Thomas ^b,c   Deng, Chu Xia ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANEUPLOIDY; ANIMAL CELL; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL CYCLE G2 PHASE; CELL DIVISION; CELL MUTANT; CELL NUCLEUS; CELL PROLIFERATION; CENTROSOME; CHROMOSOME SEGREGATION; CONTROLLED STUDY; EMBRYO; EXON; FIBROBLAST; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE TARGETING; GENETIC PREDISPOSITION; GENETIC STABILITY; MITOSIS; MOUSE; NONHUMAN; OVARY CANCER; TUMOR SUPPRESSOR GENE;

EID: 0033106326     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(00)80466-9     Document Type: Article

References (43)

1. Brugarolas, J., and Jacks, T. (1997). Double indemnity: p53 BRCA and cancer. Nat. Med. 3, 721-722.
2. Chapman, M.S., and Verma, I.M. (1996). Transcriptional activation by BRCA1. Nature 382, 678-679.
3. Chen, Y., Farmer, A.A., Chen, C.F., Jones, D.C., Chen, P.L., and Lee, W.H. (1996). BRCA1 is a 220-kda nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res. 56, 3168-3172.
4. Chen, J., Silver, D.P., Walpita, D., Cantor, S.B., Gazdar, A.F., TomlinSon, G., Couch, F.J., Weber, B.L., Ashley, T., Livingston, D.M., and Scully, R. (1998). Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol. Cell 2, 317-328.
5. Crook, T., Crossland, S., Crompton, M.R., Osin, P., and Gusterson, B.A. (1997). p53 mutations in brca1-associated familial breast cancer. Lancet 350, 638-639.
6. Deng, C., Zhang, P., Harper, J.W., Elledge, S.J., and Leder, P. (1995). Mice lacking p21Cip1/waf1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 675-684.
7. Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S., and Vande Woude, G.F. (1996). Abnormal centrosome amplification in the absence of p53. Science 271, 1744-1747.
8. Gowen, L.C., Johnson, B.L., Latour, A.M., Sulik, K.K., and Koller, B.H. (1996). Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat. Genet 12, 191-194.
9. Gowen, L.C., Avrutskaya, A.V., Latour, A.M., Koller, B.H., and LeaDon, S.A. (1998). BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 281, 1009-1012.
10. Hakem, R., de la Pompa, J.L., Sirard, C., Mo, R., Woo, M., Hakem, A., Wakeham, A., Potter, J., Reitmair, A., Billia, F., et al. (1996). The tumor suppressor gene brca1 is required for embryonic cellular proliferation in the mouse. Cell 85, 1009-1023.
11. Hakem, R., de la Pompa, J.L., Elia, A., Potter, J., and Mak, T.W. (1997). Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nat. Genet. 16, 298-302.
12. Hsu, L.C., and White, R.L. (1998). BRCA1 is associated with the centrosome during mitosis. Proc. Natl. Acad. Sci. USA 95, 12983-12988.
13. Kinzler, K.W., and Vogelstein, B. (1997). Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386, 761-763.
14. Lane, T.F., Deng, C., Elson, A., Lyu, M.S., Kozak, C.A., and Leder, P. (1995). Expression of brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes Dev. 9, 2712-2722.
15. Larson, J.S., Tonkinson, J.L., and Lai, M.T. (1997). A BRCA1 mutant alters G2-M cell cycle control in human mammary epithelial cells. Cancer Res. 57, 3351-3355.
16. Lim, D.S., and Hasty, P. (1996). A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol. Cell. Biol. 16, 7133-7143.
17. Lingle, W.L., Lutz, W.H., Ingle, J.N., Maihle, N.J., and Salisbury, J.L. (1998). Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. Proc. Natl. Acad. Sci. USA 95, 2950-2955.
18. Linke, S.P., Clarkin, K.C., and Wahl, G.M. (1997). p53 mediates permanent arrest over multiple cell cycles in response to gamma-irradiation. Cancer Res. 57, 1171-1179.
19. Liu, C.Y., Flesken-Nikitin, A., Li, S., Zeng, Y., and Lee, W.H. (1996). Inactivation of the mouse brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev. 10, 1835-1843.
20. Liyanage, M., Coleman, A., du Manoir, S., Veldman, T., McCormack, S., Dickson, R.B., Barlow, C., Wynshaw-Boris, A., Janz, S., WienBerg, J., et al. (1996). Multicolour spectral karyotyping of mouse chromosomes. Nat. Genet. 14, 312-315.
21. Ludwig, T., Chapman, D.L., Papaioannou, V.E., and Efstratiadis, A. (1997). Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev. 11, 1226-1241.
22. Meyn, M.S. (1997). Chromosome instability syndromes: lessons for carcinogenesis. Curr. Top. Microbiol. Immunol. 221, 71-148.
23. Morgan, S.E., and Kastan, M.B. (1997). p53 and ATM: cell cycle, cell death, and cancer. Adv. Cancer Res. 71, 1-25.
24. Ogawa, T., Shinohara, A., Nabetani, A., Ikeya, T., Yu, X., Egelman, E.H., and Ogawa, H. (1993). RecA-like recombination proteins in eukaryotes: Functions and structures of RAD51 genes. Cold Spring Harb. Symp. Quant. Biol. 58, 567-576.
25. Patel, K.J., Vu, V.P., Lee, H., Corcoran, A., Thistlethwaite, F.C., EvAns, M.J., Colledge, W.H., Friedman, L.S., Ponder, B.A., and VenkiTaraman, A.R. (1998). Involvement of Brca2 in DNA repair. Mol. Cell 1, 347-357.
26. Paterson, J.W. (1998). BRCA1: a review of structure and putative functions. Dis. Markers 13, 261-274.
27. Pihan, G.A., Purohit, A., Wallace, J., Knecht, H., Woda, B., QuesenBerry, P., and Doxsey, S.J. (1998). Centrosome defects and genetic instability in malignant tumors. Cancer Res. 58, 3974-3985.
28. Rudner, A.D., and Murray, A.W. (1996). The spindle assembly checkpoint. Curr. Opin. Cell Biol. 8, 773-780.
29. Ruffner, H., and Verma, I.M. (1997). BRCA1 is a cell cycle-regulated nuclear phosphoprotein. Proc. Natl. Acad. Sci. USA 94, 7138-7143.
30. Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T., and Livingston, D.M. (1997a). Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88, 265-275.
31. Scully, R., Chen, J., Ochs, R.L., Keegan, K., Hoekstra, M., Feunteun, J., and Livingston, D.M. (1997b). Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90, 425-436.
32. Sharan, S.K., Morimatsu, M., Albrecht, U., Lim, D.S., Regel, E., Dinh, C., Sands, A., Eichele, G., Hasty, P., and Bradley, A. (1997). Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386, 804-810.
33. Shen, S.X., Weaver, Z., Xu, X., Li, C., Weinstein, W., Guan, X.Y., Ried, T., and Deng, C.X. (1998). A Targeted disruption of the murine Brca1 gene causes γ-radiation hypersensitivity and genetic instability. Oncogene 17, 3115-3124.
34. Somasundaram, K., Zhang, H., Zeng, Y.X., Houvras, Y., Peng, Y., Zhang, H., Wu, G.S., Licht, J.D., Weber, B.L., and El-Deiry, W.S. (1997). Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature 389, 187-190.
35. Struewing, J.P., Hartge, P., Wacholder, S., Baker, S.M., Berlin, M., McAdams, M., Timmerman, M.M., Brody, L.C., and Tucker, M.A. (1997). The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 336, 1401-140 8.
36. Tirkkonen, M., Johannsson, O., Agnarsson, B.A., Olsson, H., IngvarsSon, S., Karhu, R., Tanner, M., Isola, J., Barkardottir, R.B., Borg, A., and Kallioniemi, O.P. (1997). Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 57, 1222-1227.
37. Tomlinson, G.E., Chen, T.T., Stastny, V.A., Virmani, A.K., Spillman, M.A., Tonk, V., Blum, J.L., Schneider, N.R., Wistuba, I.I., Shay, J.W., (1998). Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res. 58, 3237-3242.
38. Tseng, S.L., Yu, I.C., Yue, C.T., Chang, S.F., Chang, T.M., Wu, C.W., and Shen, C.Y. (1997). Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer. Genes ChromoSomes Cancer 20, 377-38 2.
39. Vaughn, J.P., Davis, P.L., Jarboe, M.D., Huper, G., Evans, A.C., WiseMan, R.W., Berchuck, A., Iglehart, J.D., Futreal, P.A., and Marks, J.R. (1996). BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ. 7, 711-715.
40. Wang, H., Shao, N., Ding, Q.M., Cui, J., Reddy, E.S., and Rao, V.N. (1997). BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants brca1a, brca1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases. Oncogene 15, 143-157.
41. Weinert, T. (1998). DNA damage and checkpoint pathways: molecular anatomy and interactions with repair. Cell 94, 555-558.
42. Winey, M. (1996). Keeping the centrosome cycle on track. Genome Stability. Curr. Biol. 6, 962-96 4.
43. Wu, L.C., Wang, Z.W., Tsan, J.T., Spillman, M.A., Phung, A., Xu, X.L., Yang, M.C., Hwang, L.Y., Bowcock, A.M., and Baer, R. (1996). Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat. Genet. 14, 430-440.